TY - JOUR
T1 - Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin
T2 - A multi-center phase II study
AU - Ichikawa, Motoshi
AU - Suzuki, Ryujiro
AU - Kataoka, Kensuke
AU - Noda, Yasunobu
AU - Shindoh, Joe
AU - Matsumoto, Syuichi
AU - Tanikawa, Yoshimasa
AU - Suzuki, Kiyoshi
AU - Baba, Kenji
AU - Shindo, Yuichiro
AU - Kondo, Masashi
AU - Imaizumi, Kazuyoshi
AU - Kume, Hiroaki
AU - Hasegawa, Yoshinori
AU - Takagi, Kenzo
AU - Taniguchi, Hiroyuki
PY - 2010/9
Y1 - 2010/9
N2 - We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI=8.2-12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.
AB - We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33-75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80mg/m2 as an intravenous infusion 60min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1-8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI=8.2-12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI=3.0-7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile.
UR - https://www.scopus.com/pages/publications/77955096246
UR - https://www.scopus.com/pages/publications/77955096246#tab=citedBy
U2 - 10.1016/j.lungcan.2009.11.021
DO - 10.1016/j.lungcan.2009.11.021
M3 - Article
C2 - 20053476
AN - SCOPUS:77955096246
SN - 0169-5002
VL - 69
SP - 319
EP - 322
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -
